Emtricitabine/Tenofovir disoproxil Zentiva
Country: Unjoni Ewropea
Lingwa: Ingliż
Sors: EMA (European Medicines Agency)
Fuljett ta 'informazzjoni
(PIL)
30-05-2023
Karatteristiċi tal-prodott
(SPC)
30-05-2023
Rapport ta 'Valutazzjoni Pubblika
(PAR)
03-10-2019
Ingredjent attiv:
emtricitabine, tenofovir disoproxil phosphate
Disponibbli minn:
Zentiva k.s.
Kodiċi ATC:
J05AR03
INN (Isem Internazzjonali):
emtricitabine, tenofovir disoproxil
Grupp terapewtiku:
Antivirals for systemic use
Żona terapewtika:
HIV Infections
Indikazzjonijiet terapewtiċi:
Treatment of HIV-1 infectionEmtricitabine/Tenofovir disoproxil Zentiva is indicated in antiretroviral combination therapy for the treatment of HIV-1 infected adults.Emtricitabine/Tenofovir disoproxil Zentiva is also indicated for the treatment of HIV-1 infected adolescents, with NRTI resistance or toxicities precluding the use of first line agents.Pre-exposure prophylaxis (PrEP)Emtricitabine/Tenofovir disoproxil Zentiva is indicated in combination with safer sex practices for pre-exposure prophylaxis to reduce the risk of sexually acquired HIV-1 infection in adults and adolescents at high risk.
Sommarju tal-prodott:
Revision: 8
L-istatus ta 'awtorizzazzjoni:
Authorised
Data ta 'l-awtorizzazzjoni:
2016-11-09
Fuljett ta 'informazzjoni
48
B. PACKAGE LEAFLET
49
PACKAGE LEAFLET: INFORMATION FOR THE USER
EMTRICITABINE/TENOFOVIR DISOPROXIL ZENTIVA 200 MG/245 MG FILM-COATED
TABLETS
emtricitabine/tenofovir disoproxil
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS
MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.
•
Keep this leaflet. You may need to read it again.
•
If you have any further questions, ask your doctor or pharmacist.
•
This medicine has been prescribed for you only. Do not pass it on to
others. It may harm them,
even if their signs of illness are the same as yours.
•
If you get any side effects, talk to your doctor or pharmacist. This
includes any possible side
effects not listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET
1.
What Emtricitabine/Tenofovir disoproxil Zentiva is and what it is used
for
2.
What you need to know before you take Emtricitabine/Tenofovir
disoproxil Zentiva
3.
How to take Emtricitabine/Tenofovir disoproxil Zentiva
4.
Possible side effects
5.
How to store Emtricitabine/Tenofovir disoproxil Zentiva
6.
Contents of the pack and other information
1.
WHAT EMTRICITABINE/TENOFOVIR DISOPROXIL ZENTIVA IS AND WHAT IT IS USED
FOR
EMTRICITABINE/TENOFOVIR DISOPROXIL ZENTIVA CONTAINS TWO ACTIVE
SUBSTANCES, emtricitabine and
tenofovir disoproxil. Both of these active substances are
antiretroviral medicines which are used to
treat HIV infection. Emtricitabine is a nucleoside reverse
transcriptase inhibitor and tenofovir is a
nucleotide reverse transcriptase inhibitor. However, both are
generally known as NRTIs and they work
by interfering with the normal working of an enzyme (reverse
transcriptase) that is essential for the
virus to reproduce itself.
•
EMTRICITABINE/TENOFOVIR DISOPROXIL ZENTIVA IS USED TO TREAT HUMAN
IMMUNODEFICIENCY
VIRUS 1(HIV-1) INFECTION, IN ADULTS.
•
IT IS ALSO USED TO TREAT HIV IN ADOLESCENTS AGED 12 TO LESS THAN 18
YEARS WHO WEIGH AT LEAST
35 KG, and who have already been treated with other HIV medicines that
are no longer effective
or have caused side eff
Aqra d-dokument sħiħ
Karatteristiċi tal-prodott
1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE MEDICINAL PRODUCT
Emtricitabine/Tenofovir disoproxil Zentiva 200 mg / 245 mg film-coated
tablets
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each film-coated tablet contains 200 mg of emtricitabine and 245 mg of
tenofovir disoproxil
(equivalent to 291.5 mg of tenofovir disoproxil phosphate or 136 mg of
tenofovir).
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Film-coated tablet.
Blue, oval biconvex film-coated tablet without half-score with
dimensions approx. 19.35 x 9.75 mm.
4.
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
_ _
Treatment of HIV-1 infection
Emtricitabine/Tenofovir disoproxil Zentiva is indicated in
antiretroviral combination therapy for the
treatment of HIV-1 infected adults (see section 5.1).
Emtricitabine/Tenofovir disoproxil Zentiva is also indicated for the
treatment of HIV-1 infected
adolescents, with NRTI resistance or toxicities precluding the use of
first line agents (see sections 4.2,
4.4 and 5.1).
Pre-exposure prophylaxis (PrEP)
Emtricitabine/Tenofovir disoproxil Zentiva is indicated in combination
with safer sex practices for
pre-exposure prophylaxis to reduce the risk of sexually acquired HIV-1
infection in adults and
adolescents at high risk (see sections 4.2, 4.4 and 5.1).
4.2
POSOLOGY AND METHOD OF ADMINISTRATION
Emtricitabine/Tenofovir disoproxil Zentiva should be initiated by a
physician experienced in the
management of HIV infection.
Posology
_ _
_Treatment of HIV in adults_
_and adolescents aged 12 years and older, weighing at least 35 kg_
One tablet, once daily.
_Prevention of HIV in adults and adolescents aged 12 years and older,
weighing at least 35 kg_
One tablet, once daily.
Separate preparations of emtricitabine and tenofovir disoproxil are
available for treatment of HIV-1
infection if it becomes necessary to discontinue or modify the dose of
one of the components of
Emtricitabine/Tenofovir disoproxil Zentiva. Please refer to the
Summary of Product Characteristics
for these medicina
Aqra d-dokument sħiħ
